Company profile
Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05304377 | phase1 | recruiting | 2022-05-22 | 2027-12-01 | Enliven Therapeutics | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia |
| NCT06787144 | phase1 | recruiting | 2025-01-23 | 2028-01-01 | Enliven Therapeutics | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants |
| NCT06328738 | phase1 | active_not_recruiting | 2024-05-30 | 2027-01-01 | Enliven Therapeutics | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
| NCT05650879 | phase1 | active_not_recruiting | 2023-03-20 | 2026-07-01 | Enliven Therapeutics | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer |
FDA applications (0)
No records yet.